Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29919690 | 0.86 | ALDH1A1 (0.47) | MAPTALDH1A1LMNAGPR119MAP4K4 | |
| SCHEMBL30635685 | 0.84 | MAPT (0.51) | MAPTALDH1A1LMNAGPR119MAP4K4 | |
| SCHEMBL29608605 | 0.84 | MAPT (0.58) | MAPTALDH1A1LMNAGPR174L3MBTL1 | |
| SCHEMBL28773828 | 0.84 | MAPT (0.58) | MAPTALDH1A1LMNAGPR174L3MBTL1 | |
| SCHEMBL3624023 | 0.82 | AR (0.52) | MAPTALDH1A1LMNAGPR119MAP4K4 | |
| SCHEMBL18186321 | 0.82 | MAPT (0.76) | MAPTALDH1A1LMNAGPR119MAP4K4 | |
| SCHEMBL13419658 | 0.82 | MAPT (0.76) | MAPTALDH1A1LMNAGPR119MAP4K4 | |
| SCHEMBL31337316 | 0.80 | MAPT (0.58) | MAPTALDH1A1LMNAGPR119MAP4K4 | |
| SCHEMBL24383785 | 0.80 | ALDH1A1 (0.50) | MAPTALDH1A1LMNAGPR119MAP4K4 | |
| SCHEMBL13156574 | 0.80 | GPR119 (0.47) | MAPTALDH1A1LMNAGPR119MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289719-A1 | HETEROCYCLIC COMPOUNDS AS MNK INHIBITORS | NANJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289719-A1 | HETEROCYCLIC COMPOUNDS AS MNK INHIBITORS | NIM1K, MAP3K1, MAPKAPK2 | MAPT 1243/4885ALDH1A1 4284/4885LMNA 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.